Anti-EFNA4 calicheamicin conjugates effectively target triple-negative breast and ovarian tumor-initiating cells to result in sustained tumor regressions

Clinical Cancer Research

Volumn 21, Issue 18, 2015, Pages 4165-4173

  Damelin, Marc ^a   Bankovich, Alexander ^b   Park, Albert ^b   Aguilar, Jorge ^b   Anderson, Wade ^b   Santaguida, Marianne ^b   Aujay, Monette ^b   Fong, Sarah ^b   Khandke, Kiran ^a   Pulito, Virginia ^a   Ernstoff, Elana ^a   Escarpe, Paul ^b   Bernstein, Jeffrey ^b   Pysz, Marybeth ^b   Zhong, Wenyan ^a   Upeslacis, Erik ^a   Lucas, Judy ^a   Lucas, Justin ^a   Nichols, Timothy ^a   Loving, Kathryn ^b   Foord, Orit ^b   Hampl, Johannes ^b   Stull, Robert ^b   Barletta, Frank ^a   Falahatpisheh, Hadi ^a   Sapra, Puja ^a   Gerber, Hans Peter ^a   Dylla, Scott J ^b   more..

^a PFIZER INC   (United States)

^b Stemcentrx   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; EPHRIN A4; EPHRIN A4 ANTIBODY CALICHEAMICIN CONJUGATE; IRINOTECAN; UNCLASSIFIED DRUG; UVOMORULIN; AMINOGLYCOSIDE; CALICHEAMICIN GAMMA(1)I; DNA; ENEDIYNE; MONOCLONAL ANTIBODY; PF-06647263; TUMOR ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG TOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VIVO STUDY; MACACA FASCICULARIS; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRIPLE NEGATIVE BREAST CANCER; TUMOR CELL; TUMOR INITIATING CELL; TUMOR REGRESSION; TUMOR XENOGRAFT; ANIMAL; CANCER STEM CELL; CHEMISTRY; DRUG DESIGN; DRUG SCREENING; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HEK293 CELL LINE; METABOLISM; NONOBESE DIABETIC MOUSE; OVARIAN NEOPLASMS; PROSPECTIVE STUDY; RANDOMIZATION; SCID MOUSE; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR CELL LINE;

AMINOGLYCOSIDES; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, NEOPLASM; CELL LINE, TUMOR; DNA; DRUG DESIGN; ENEDIYNES; EPHRIN-A4; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HUMANS; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASTIC STEM CELLS; OVARIAN NEOPLASMS; PROSPECTIVE STUDIES; RANDOM ALLOCATION; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84942898855     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-0695     Document Type: Article

References (47)

1. Lin NU, Vanderplas A, Hughes ME, Theriault RL, Edge SB, Wong YN, et al. Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer 2012;118:5463-72.
2. Bramati A, Girelli S, Torri V, Farina G, Galfrascoli E, Piva S, et al. Efficacy of biological agents in metastatic triple-negative breast cancer. Cancer Treat Rev 2014;40:605-13.
3. Yadav BS, Sharma SC, Chanana P, Jhamb S. Systemic treatment strategies for triple-negative breast cancer. World J Clin Oncol 2014;5:125-33.
4. Duska LR, Garrett A, Eltabbakh GH, Oliva E, Penson R, Fuller AF. Paclitaxel and platinum chemotherapy for malignantmixed mullerian tumors of the ovary. Gynecol Oncol 2002;85:459-63.
5. McCluggage WG. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. Pathology 2011;43:420-32.
6. Loizzi V, Cormio G, Camporeale A, Falagario M, De Mitri P, Scardigno D, et al. Carcinosarcoma of the ovary: analysis of 13 cases and review of the literature. Oncology 2011;80:102-6.
7. Prat J. New insights into ovarian cancer pathology. Ann Oncol 2012;23: x111-7.
8. Cantley LC, Dalton WS, DuBois RN, Finn OJ, Futreal PA, Golub TR, et al. AACR Cancer Progress Report 2012. Clin Cancer Res 2012;18: S1-100.
9. Coleman RL, MonkBJ, Sood AK, Herzog TJ. Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol 2013;10: 211-24.
10. Tentler JJ, Tan AC, Weekes CD, Jimeno A, Leong S, Pitts TM, et al. Patientderived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol 2012;9:338-50.
11. Williams SA, Anderson WC, Santaguida MT, Dylla SJ. Patient-derived xenografts, the cancer stem cell paradigm, and cancer pathobiology in the 21st century. Lab Invest 2013;93:970-82.
12. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003;100:3983-8.
13. Jin K, Teng L, Shen Y, He K, Xu Z, Li G. Patient-derived human tumour tissue xenografts in immunodeficient mice: a systematic review. Clin Transl Oncol 2010;12:473-80.
14. DeRose YS, Wang G, Lin YC, Bernard PS, Buys SS, Ebbert MT, et al. Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat Med 2011; 17:1514-20.
15. Rosfjord E, Lucas J, Li G, Gerber HP. Advances in patient-derived tumor xenografts: from target identification to predicting clinical response rates in oncology. Biochem Pharmacol 2014;91:135-43.
16. Pasquale EB. Eph receptor signalling casts a wide net on cell behaviour. Nat Rev Mol Cell Biol 2005;6:462-75.
17. Pasquale EB. Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat Rev Cancer 2010;10:165-80.
18. Kaenel P, Mosimann M, Andres AC. The multifaceted roles of Eph/ephrin signaling in breast cancer. Cell Adh Migr 2012;6:138-47.
19. Lin S, Wang B, Getsios S. Eph/ephrin signaling in epidermal differentiation and disease. Semin Cell Dev Biol 2012;23:92-101.
20. Brantley-Sieders DM, Jiang A, Sarma K, Badu-Nkansah A, Walter DL, Shyr Y, et al. Eph/ephrin profiling in human breast cancer reveals significant associations between expression level and clinical outcome. PloS One 2011;6:e24426.
21. Hafner C, Schmitz G, Meyer S, Bataille F, Hau P, Langmann T, et al. Differential gene expression of Eph receptors and ephrins in benign human tissues and cancers. Clin Chem 2004;50:490-9.
22. Surawska H, Ma PC, Salgia R. The role of ephrins and Eph receptors in cancer. Cytokine Growth Factor Rev 2004;15:419-33.
23. Boyd AW, Bartlett PF, LackmannM. Therapeutic targeting of EPH receptors and their ligands. Nat Rev Drug Discov 2014;13:39-62.
24. Sapra P, Hooper AT, O'Donnell CJ, Gerber HP. Investigational antibody drug conjugates for solid tumors. Expert Opin Investig Drugs 2011; 20:1131-49.
25. Sievers EL, Senter PD. Antibody-drug conjugates in cancer therapy. Annu Rev Med 2013;64:15-29.
26. Gerber HP, Koehn FE, Abraham RT. The antibody-drug conjugate: an enabling modality for natural product-based cancer therapeutics. Nat Prod Rep 2013;30:625-39.
27. Mullard A. Maturing antibody-drug conjugate pipeline hits 30. Nat Rev Drug Discov 2013;12:329-32.
28. Lambert JM, Chari RV. Ado-trastuzumab Emtansine (T-DM1): an antibody- drug conjugate (ADC) for HER2-positive breast cancer. J Med Chem 2014;57:6949-64.
29. Senter PD, Sievers EL. The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat Biotechnol 2012;30:631-7.
30. Nicolaou KC, Pitsinos EN, Theodorakis EA, Saimoto H, Wrasidlo W. Synthetic calicheamicin mimics with novel initiation mechanisms: DNA cleavage, cytotoxicity, and apoptosis. Chem Biol 1994;1:57-66.
31. Prokop A, Wrasidlo W, Lode H, Herold R, Lang F, Henze G, et al. Induction of apoptosis by enediyne antibiotic calicheamicin thetaII proceeds through a caspase-mediated mitochondrial amplification loop in an entirely Baxdependent manner. Oncogene 2003;22:9107-20.
32. Zein N, Sinha AM, McGahren WJ, Ellestad GA. Calicheamicingamma 1I: an antitumor antibiotic that cleaves double-stranded DNA site specifically. Science 1988;240:1198-201.
33. Dalerba P, Dylla SJ, Park IK, Liu R, Wang X, Cho RW, et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci U S A 2007;104:10158-63.
34. Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 2010;12:R68.
35. Prat A, Perou CM. Deconstructing the molecular portraits of breast cancer. Mol Oncol 2011;5:5-23.
36. Stephens PJ, Tarpey PS, Davies H, Van Loo P, Greenman C, Wedge DC, et al. The landscape of cancer genes and mutational processes in breast cancer. Nature 2012;486:400-4.
37. Curtis C, Shah SP, Chin SF, TurashviliG, Rueda OM, Dunning MJ, et al. The genomic and transcriptomic architecture of 2, 000 breast tumours reveals novel subgroups. Nature 2012;486:346-52.
38. Mah LJ, El-Osta A, Karagiannis TC. gammaH2AX: a sensitive molecular marker of DNA damage and repair. Leukemia 2010;24:679-86.
39. Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. Nature 2012;490:61-70.
40. Cancer Genome Atlas Research N. Integrated genomic analyses of ovarian carcinoma. Nature 2011;474:609-15.
41. AnnunziataCM, Kohn EC, LoRusso P, Houston ND, Coleman RL, Buzoianu M, et al. Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors. Investig New Drugs 2013;31:77-84.
42. Golfier S, Kopitz C, Kahnert A, Heisler I, Schatz CA, Stelte-Ludwig B, et al. Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect. Mol Cancer Ther 2014;13:1537-48.
43. Govindan SV, Cardillo TM, Moon SJ, Hansen HJ, Goldenberg DM. CEACAM5- targeted therapy of human colonic and pancreatic cancer xenografts with potent labetuzumab-SN-38 immunoconjugates. Clin Cancer Res 2009;15:6052-61.
44. Kelly RK, Olson DL, Sun Y, Wen D, Wortham KA, Antognetti G, et al. An antibody-cytotoxic conjugate, BIIB015, is a new targeted therapy for Cripto positive tumours. Eur J Cancer 2011;47:1736-46.
45. Burleigh A, McKinney S, Brimhall J, Yap D, Eirew P, Poon S, et al. A coculture genome-wide RNAi screen with mammary epithelial cells reveals transmembrane signals required for growth and differentiation. Breast Cancer Res 2015;17:4.
46. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008;133:704-15.
47. Morel AP, Lievre M, Thomas C, Hinkal G, Ansieau S, Puisieux A. Generation of breast cancer stem cells through epithelial-mesenchymal transition. PloS One 2008;3:e2888.